KUALA LUMPUR: Duopharma Biotech Bhd
foresees challenges from a strong US dollar, high electricity tariffs, and interest rates impacting manufacturing margins and overall profitability, says group managing director Leonard Ariff Abdul Shatar.
“However, the group remains focused on enhancing operational efficiencies internally to cushion the surge in operational and finance costs caused by these challenges,” Leonard said in a statement.
